PsychotherapyDigital healthBehavioral
What this study is
To learn more about your experience participating in a virtual Meaning-Centered Psychotherapy group.
What's being tested
- Therapy
Intervention · OTHER
MCGP will be delivered in 8 weekly sessions for 90 minutes over Zoom by a licensed doctoral level psychologist.
Study details
- Sponsor
- M.D. Anderson Cancer Center
- Conditions
- Psychotherapy · Integrative Medicine
- Enrolling
- 72 people
- Starts
- 2025-10-03
- Est. completion
- 2029-02-01
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Eligibility Criteria
- Age 18 or older.
- Male or female.
- Diagnosis or history of malignant cancer (excluding non-melanoma skin cancer) or tumor disease.
- Able to read, write, and speak in English.
- Has access to iOS or Android smartphone, computer, or tablet or device capable of logging onto Zoom.
- Referred to the Integrative Medicine Clinic, completed consult with IMC physician, referred to health psychology and completed health psychology assessment.
- Participates in at least one MCGP group session.
- Willing to review informed consent statement and agree to complete questionnaires.
You can't join if
- Children will not be enrolled in this study.
- Pregnant women will not be enrolled in this study.
- Cognitively impaired subjects will not be enrolled in this study.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openMD Anderson Cancer Center
Houston, Texas, United States
- Elizabeth C Conti, MD · Contact713-563-7630ecconti@mdanderson.org
- Elizabeth C Conti, MD · Principal investigator
Recruiting
Study team
Sponsor
M.D. Anderson Cancer Center
Study ID 2025-0994
Principal investigator
Elizabeth C Conti, MD
M.D. Anderson Cancer Center
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.